FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005376769> ?p ?o ?g. }

• W3005376769 endingPage "240" @default.
• W3005376769 startingPage "231" @default.
• W3005376769 abstract "•Despite high-intensity statins, few FH subjects achieve the recommended LDL-C goal. •We investigated the effectiveness of PCSK9-i or ezetimibe in FH subjects. •After 6 months, most patients reaching LDL-C goal were in the PCSK9-i group. •The PCSK9-i group achieved both a greater LDL-C and PWV reduction than the EZE group. •A linear regression analysis showed a relationship between ΔPWV and ΔLDL. Background Familial hypercholesterolemia (FH) is characterized by increased cardiovascular risk; despite-high intensity statins, only few patients with FH achieve the recommended low-density lipoprotein cholesterol (LDL-C) targets. Objective We aimed to evaluate the effectiveness of six-month add-on therapy with proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) or ezetimibe on lipid profile and pulse wave velocity (PWV) in patients with FH. Methods In this observational study, we evaluated 98 genetically confirmed patients with FH with an LDL-C off-target despite high-intensity statins with or without ezetimibe; of these, 53 patients (statin plus ezetimibe) added PCSK9-i (PCSK9-i group) and 45 (statin only) added ezetimibe (EZE group) per applicable guidelines and reimbursement rules. All patients obtained biochemical analysis and PWV evaluation at baseline and after six months of optimized treatment. Results After 6 months of add-on therapy, most patients achieving LDL-C targets were in the PCSK9-i group (77.3% PCSK9-i group vs 37.8% EZE group, P < .001). The PCSK9-i group achieved both a greater LDL-C and PWV reduction than the EZE group [−51% vs −22.8%, P < .001 and −15% vs −8.5%, P < .01, respectively]. In a linear regression analysis, we showed a coefficient (r) of 0.334 for the relationship between ΔPWV and ΔLDL (P < .05); moreover, in an exploratory analysis, the relationship appeared to be stronger in patients with FH without cardiovascular events (r = 0.422, P < .01). Conclusions Lipid and PWV profiles in patients with FH significantly improved after addition of PCSK9-i or ezetimibe to high-intensity statin therapy; moreover, ΔPWV was associated with ΔLDL. Our results are consistent with a beneficial role of these novel therapies in FH subjects. Familial hypercholesterolemia (FH) is characterized by increased cardiovascular risk; despite-high intensity statins, only few patients with FH achieve the recommended low-density lipoprotein cholesterol (LDL-C) targets. We aimed to evaluate the effectiveness of six-month add-on therapy with proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) or ezetimibe on lipid profile and pulse wave velocity (PWV) in patients with FH. In this observational study, we evaluated 98 genetically confirmed patients with FH with an LDL-C off-target despite high-intensity statins with or without ezetimibe; of these, 53 patients (statin plus ezetimibe) added PCSK9-i (PCSK9-i group) and 45 (statin only) added ezetimibe (EZE group) per applicable guidelines and reimbursement rules. All patients obtained biochemical analysis and PWV evaluation at baseline and after six months of optimized treatment. After 6 months of add-on therapy, most patients achieving LDL-C targets were in the PCSK9-i group (77.3% PCSK9-i group vs 37.8% EZE group, P < .001). The PCSK9-i group achieved both a greater LDL-C and PWV reduction than the EZE group [−51% vs −22.8%, P < .001 and −15% vs −8.5%, P < .01, respectively]. In a linear regression analysis, we showed a coefficient (r) of 0.334 for the relationship between ΔPWV and ΔLDL (P < .05); moreover, in an exploratory analysis, the relationship appeared to be stronger in patients with FH without cardiovascular events (r = 0.422, P < .01). Lipid and PWV profiles in patients with FH significantly improved after addition of PCSK9-i or ezetimibe to high-intensity statin therapy; moreover, ΔPWV was associated with ΔLDL. Our results are consistent with a beneficial role of these novel therapies in FH subjects." @default.
• W3005376769 created "2020-02-14" @default.
• W3005376769 creator A5011482278 @default.
• W3005376769 creator A5017734003 @default.
• W3005376769 creator A5026694842 @default.
• W3005376769 creator A5040457683 @default.
• W3005376769 creator A5052729205 @default.
• W3005376769 creator A5054429253 @default.
• W3005376769 creator A5058571697 @default.
• W3005376769 creator A5081405968 @default.
• W3005376769 creator A5083690016 @default.
• W3005376769 creator A5084141725 @default.
• W3005376769 creator A5087271401 @default.
• W3005376769 creator A5087621587 @default.
• W3005376769 creator A5089855166 @default.
• W3005376769 date "2020-03-01" @default.
• W3005376769 modified "2023-10-05" @default.
• W3005376769 title "Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two–Lipid Center Real-World Experience" @default.
• W3005376769 cites W1520609538 @default.
• W3005376769 cites W1993634977 @default.
• W3005376769 cites W2001328643 @default.
• W3005376769 cites W2006051875 @default.
• W3005376769 cites W2030958629 @default.
• W3005376769 cites W2035128451 @default.
• W3005376769 cites W2064328378 @default.
• W3005376769 cites W2093812341 @default.
• W3005376769 cites W2104299102 @default.
• W3005376769 cites W2111099202 @default.
• W3005376769 cites W2130842763 @default.
• W3005376769 cites W2135545256 @default.
• W3005376769 cites W2140847494 @default.
• W3005376769 cites W2143691602 @default.
• W3005376769 cites W2147346175 @default.
• W3005376769 cites W2153027090 @default.
• W3005376769 cites W2165624352 @default.
• W3005376769 cites W2170452015 @default.
• W3005376769 cites W2207858820 @default.
• W3005376769 cites W2298508936 @default.
• W3005376769 cites W2508964286 @default.
• W3005376769 cites W2594072057 @default.
• W3005376769 cites W2596179513 @default.
• W3005376769 cites W2596501540 @default.
• W3005376769 cites W2610355229 @default.
• W3005376769 cites W2738464036 @default.
• W3005376769 cites W2757199879 @default.
• W3005376769 cites W2757992992 @default.
• W3005376769 cites W2759090324 @default.
• W3005376769 cites W2760771213 @default.
• W3005376769 cites W2761079932 @default.
• W3005376769 cites W2776147158 @default.
• W3005376769 cites W2778792421 @default.
• W3005376769 cites W2787063037 @default.
• W3005376769 cites W2803057033 @default.
• W3005376769 cites W2848978533 @default.
• W3005376769 cites W2884122380 @default.
• W3005376769 cites W2888589263 @default.
• W3005376769 cites W2892662764 @default.
• W3005376769 cites W2894417323 @default.
• W3005376769 cites W2899997727 @default.
• W3005376769 cites W2902745272 @default.
• W3005376769 cites W2913505262 @default.
• W3005376769 cites W2937069950 @default.
• W3005376769 cites W2946215404 @default.
• W3005376769 cites W4236673002 @default.
• W3005376769 cites W4238580056 @default.
• W3005376769 cites W867395513 @default.
• W3005376769 doi "https://doi.org/10.1016/j.jacl.2020.01.015" @default.
• W3005376769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32111581" @default.
• W3005376769 hasPublicationYear "2020" @default.
• W3005376769 type Work @default.
• W3005376769 sameAs 3005376769 @default.
• W3005376769 citedByCount "31" @default.
• W3005376769 countsByYear W30053767692020 @default.
• W3005376769 countsByYear W30053767692021 @default.
• W3005376769 countsByYear W30053767692022 @default.
• W3005376769 countsByYear W30053767692023 @default.
• W3005376769 crossrefType "journal-article" @default.
• W3005376769 hasAuthorship W3005376769A5011482278 @default.
• W3005376769 hasAuthorship W3005376769A5017734003 @default.
• W3005376769 hasAuthorship W3005376769A5026694842 @default.
• W3005376769 hasAuthorship W3005376769A5040457683 @default.
• W3005376769 hasAuthorship W3005376769A5052729205 @default.
• W3005376769 hasAuthorship W3005376769A5054429253 @default.
• W3005376769 hasAuthorship W3005376769A5058571697 @default.
• W3005376769 hasAuthorship W3005376769A5081405968 @default.
• W3005376769 hasAuthorship W3005376769A5083690016 @default.
• W3005376769 hasAuthorship W3005376769A5084141725 @default.
• W3005376769 hasAuthorship W3005376769A5087271401 @default.
• W3005376769 hasAuthorship W3005376769A5087621587 @default.
• W3005376769 hasAuthorship W3005376769A5089855166 @default.
• W3005376769 hasBestOaLocation W30053767692 @default.
• W3005376769 hasConcept C126322002 @default.
• W3005376769 hasConcept C164705383 @default.
• W3005376769 hasConcept C2775850156 @default.
• W3005376769 hasConcept C2776839432 @default.
• W3005376769 hasConcept C2778163477 @default.
• W3005376769 hasConcept C2778319312 @default.
• W3005376769 hasConcept C2778657065 @default.

• next